These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1348 related articles for article (PubMed ID: 25805920)
1. Update on the management of pancreatic cancer: surgery is not enough. Ansari D; Gustafsson A; Andersson R World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920 [TBL] [Abstract][Full Text] [Related]
2. New challenges in perioperative management of pancreatic cancer. Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134 [TBL] [Abstract][Full Text] [Related]
3. Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A; Juarez V World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356 [TBL] [Abstract][Full Text] [Related]
4. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723 [TBL] [Abstract][Full Text] [Related]
5. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695 [TBL] [Abstract][Full Text] [Related]
8. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Borazanci E; Sckolnik S; Amini A Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348 [TBL] [Abstract][Full Text] [Related]
9. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786 [TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
11. The importance of surgical margins in pancreatic cancer. Ethun CG; Kooby DA J Surg Oncol; 2016 Mar; 113(3):283-8. PubMed ID: 26603829 [TBL] [Abstract][Full Text] [Related]
12. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211 [TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer subtypes: a roadmap for precision medicine. Torres C; Grippo PJ Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193 [TBL] [Abstract][Full Text] [Related]
15. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090 [TBL] [Abstract][Full Text] [Related]
16. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer. Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394 [TBL] [Abstract][Full Text] [Related]